1. Academic Validation
  2. Discovery of Novel, Orally Bioavailable Pyrimidine Ether-Based Inhibitors of ELOVL1

Discovery of Novel, Orally Bioavailable Pyrimidine Ether-Based Inhibitors of ELOVL1

  • J Med Chem. 2021 Dec 23;64(24):17777-17794. doi: 10.1021/acs.jmedchem.1c00948.
Michael J Boyd 1 Philip N Collier 1 Michael P Clark 1 Hongbo Deng 1 Sarathy Kesavan 1 Steven M Ronkin 1 Nathan Waal 1 Jian Wang 1 Jingrong Cao 1 Pan Li 1 Jon Come 1 Ioana Davies 1 John P Duffy 1 John E Cochran 1 John J Court 1 Kishan Chandupatla 1 Katrina L Jackson 1 Francois Maltais 1 Hardwin O'Dowd 1 Christina Boucher 1 Tony Considine 1 William P Taylor 1 Hong Gao 1 Ananthisrinivas Chakilam 1 Juntyma Engtrakul 1 Dan Crawford 1 Elizabeth Doyle 1 Jonathan Phillips 1 Raymond Kemper 1 Rebecca Swett 1 James Empfield 1 Mark E Bunnage 1 Paul S Charifson 1 Sanjay Shivayogi Magavi 1
Affiliations

Affiliation

  • 1 Vertex Pharmaceuticals Incorporated, 50 Northern Ave, Boston, Massachusetts 02210, United States.
Abstract

In our efforts to identify novel small molecule inhibitors for the treatment of adrenoleukodystrophy (ALD), we conducted a high-throughput radiometric screen for inhibitors of elongation of very long chain fatty acid 1 (ELOVL1) Enzyme. We developed a series of highly potent, central nervous system (CNS)-penetrant pyrimidine ether-based compounds with favorable pharmacokinetics culminating in compound 22. Compound 22 is a selective inhibitor of ELOVL1, reducing C26:0 VLCFA synthesis in ALD patient fibroblasts and lymphocytes in vitro. Compound 22 reduced C26:0 lysophosphatidyl choline (LPC), a subtype of VLCFA, in the blood of ATP binding cassette transporter D1 (ABCD1) KO mice, a murine model of ALD to near wild-type levels. Compound 22 is a low-molecular-weight, potent ELOVL1 inhibitor that may serve as a useful tool for exploring therapeutic approaches to the treatment of ALD.

Figures
Products